© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Laura Joszt
Laura is the editorial director of The American Journal of Managed Care® (AJMC®) and all its brands, including The American Journal of Accountable Care®, Evidence-Based Oncology™, and The Center for Biosimilars®. She has been working on AJMC® since 2014 and has been with AJMC®'s parent company, MJH Life Sciences®, since 2011. She has an MA in business and economic reporting from New York University.
You can reach her at ljoszt@mjhlifesciences.com or you can connect with her on LinkedIn or Twitter.
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
December 07, 2023
Article
A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Payer Controls Limiting Semglee Uptake Despite Patient Demand
July 20, 2023
Article
A new analysis finds branded insulin glargine (Lantus) still has a majority of total market volume and new drug starts despite competition from Semglee, an interchangeable biosimilar.
Sandoz Roadmap Aims to Increase Worldwide Biosimilar Adoption by 2030
June 27, 2023
Article
The Act4Biosimilars Action Plan seeks to increase biosimilar adoption by at least 30 percentage points in 30-plus countries by 2030.
Medicare 340B Program May Be Reducing Biosimilar Uptake
June 08, 2023
Article
New research has found the 340B program is slowing uptake of biosimilars by incentivizing use of more expensive biologics.
Employer Playbook Suggests Strategies for Biosimilar Adoption, Navigating Adalimumab Launches
March 09, 2023
Article
A new resource from the National Alliance of Healthcare Purchaser Coalitions aims to help plan sponsors adopt biosimilars into their pharmacy benefit plans.
AJMC: The Top 5 Most Popular Biosimilars Content of 2022
December 27, 2022
Article
The American Journal of Managed Care, a sister site of The Center for Biosimilars, looked back at some of the most popular biosimilars content of 2022 to be published on AJMC.com.
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
May 30, 2022
Article
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability, the US market is entering a new phase of biosimilar use.
The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei
May 03, 2022
Article
The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.
Pegfilgrastim Biosimilars Provide Clinical, Economic Benefits to Prevent Febrile Neutropenia
April 18, 2022
Article
An analysis of real-world dosing and effectiveness of pegfilgrastim biosimilars found the clinical benefits of preventing febrile neutropenia in patients with intermediate to high risk come at acceptable financial costs compared with filgrastim biosimilars.
Biosimilar Competition and Utilization Uptake Have Driven Down Costs in the Oncology Space
April 01, 2022
Article
During a session at the Academy of Managed Care Pharmacy annual meeting, Yuqian Liu, PharmD, of Magellan Rx Management, highlighted strategies to encourage biosimilar utilization in the oncology space and the cost savings as a result.